All News

Inflation is the top reason that nearly one-third of Americans are concerned about covering unexpected health care needs

We may be one step closer to nonprescription naloxone.

Your weekly roundup of the latest news from Drug Topics®.

As a health plan worked to boost medication adherence among members, it made a startling discovery.

Your weekly roundup of the latest news from Drug Topics®.

Acid sphingomyelinase deficiency is a rare, progressive genetic disease associated with significant morbidity and mortality.

A look at what’s to come in the November issue of Drug Topics®

Take a look back at our most popular news from October 2022.

In a recent poll, only 1 in 5 parents believed it is unsafe for children to take medicine past its expiration date, while many did not know how to properly dispose medicine.

Dry shampoo products were found to contain elevated levels of Benzene.

Antibiotics are often administered to pediatric patients at end of life, even in cases without infection.

Adult vaccine uptake lags and understanding the reasons could be important.

Your weekly roundup of the latest news from Drug Topics®.

Determining the characteristics that impact antibiotic prescribing behavior is important for addressing health inequity.

IDWeek is taking place in person for the first time in 3 years.

Two reports show that drug-related deaths are skyrocketing among people 65 years and older.

Share your thoughts on this year in review.

Your weekly roundup of the latest news from Drug Topics®.

From biosimilars to artificial intelligence, these are the trends poised to take community pharmacy by storm.

Make mental health a priority.

Readers, we want to hear from you.

A look at what’s to come in the October issue of Drug Topics®

SingleCare's 4th annual celebration of the best in pharmacy, from pharmacists to pharmacy technicians and teams across the United States has been announced.

Your weekly roundup of the latest news from Drug Topics®.

The move is meant to expand access to reproductive health care for women in the state.

The new guidance aims to improve supply for harm reduction programs.

Now with the brand name Relyvrio, the new therapy should be available within four to six weeks. It will have a wholesale acquisition cost of $158,000 per year.